Vamshi Rao, MD, attending physician of Neurology at Ann and Robert H. Lurie Children’s Hospital of Chicago, discusses the future of combination therapies in the spinal muscular atrophy (SMA) space.
Vamshi Rao, MD, is an attending physician of Neurology at Ann and Robert H. Lurie Children’s Hospital of Chicago and assistant professor of Pediatrics (Neurology and Epilepsy) at Northwestern University Feinberg School of Medicine.
Transcript:
What future do you see for combination therapies in SMA and how will they affect patient outcomes?
Rao: I think we are definitely seeing a push for combination therapies from the patient point of view but also from the scientific community in general. I think what we are struggling with, of course, is lack of data in terms of using combination therapies in the real world. We have 3 drugs approved. You would think that we would have the discretion of prescribing those drugs as a combination, but it's hard because there is no clinical trial evidence of that. So, I think most of the sponsors and pharmaceutical companies that own these drugs are looking forward to some data out there that can result in a combination product, whether it is a trial where their drug is the first to be given or whether their drug is the one that follows a drug. For example, because nusinersen [Spinraza] was approved in 2016 and most folks started with nusinersen, there are now trials looking at a whether coming in with a drug after nusinersen, such as, Zogensma [onasemnogene abeparvovec] or Evrysdi [risdiplam], would be more beneficial. More so, I think people are also looking at safety of when to use combination therapy.
Right now, there isn't much data out there, [except for] some publications, about real world experiences. A group that I work with published a paper where we looked at children who had nusinersen or Zolgensma and then got the other drug, whether it was nusinersen or Zolgensma. So, it's small studies. I don't think we can generalize results yet. Definitely, I do see that combination therapies are going to be the wave of the future and I say that because unless you have 1 drug that has been instituted early in life, that leads to a child or an individual who looks like a non-SMA child, there is going to be a quest for something better, something more. So, if you have had a drug that makes you attain motor milestones, and jumpstarts your development, but you don't reach the curve or follow the curve of development of a non-SMA trial, then there's still some scope to bridge the gap. That's where the question about what's next, whether it's a new drug or a combination of drugs, is going to happen.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More